- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01548508
Evaluation of Functionnal ElectromyoStimulation on Leg In Advanced Chronic Heart Failure After Hospitalisation for Acute Decompensation (EMSICA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Advanced Chronic Heart Failure (ACHF) is a severe and frequent disease inducing a strong limitation of exercise capacity and a poor quality of life. Hospitalisation for cardiac decompensation is frequent and could alter their incapacities because of muscular deconditionning. Tradionnal aerobic rehabilitation exercises fighting against this deconditionning are not relevant in these patients because of dyspnea.
In litterature, Functionnal Electrostimulation (FES) has been tested in stable Chronic Heart Failure (NYHA I to III), far from decompensation. Several authors showed the same improvements than those obtained with conventionnal rehabilitation on aerobic capacities (peak VO2, 6 minutes walking test) and quality of life.
The originality of this study is to test FES soon after acute heart decompensation in ACHF patients. This type of rehabilitation could represent in the future an alternative to conventionnal rehabilitation until the patients could be able to do aerobic exercise.
60 patients will be randomised between two groups, the firsth receiving FES (treatment group), the second receiving skin electrostimulation in the same place without muscular contraction (Sham group). Patient and evaluator do not know what type of stimulation they have. These treatments spread over six weeks, five days per seven. They are began in rehabilitation unit then continued at home.
The principal criteria of judgement of FES efficacy is peak VO2 after the protocol. Secondary criteria are distance to the six minutes walking test, muscular strengh of quadriceps, the muscle mass measured by Dual energy X-ray absorptiometry (DEXA), inflamatory dosage (TNF alpha, IL-1, IL-6, CRP), rest value of Muscle sympathetic nerve activity, score to Minnesota questionnaire and fuctionnal independance.
The attempted results are an significative improvement of aerobic capacity(peak VO2 and six minutes walking test) and the others secondary criteria in FES group compared with Sham group.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- Universty Hospital Toulouse Cardiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Advanced Chronic Heart Failure (NYHA III to IV)
- Cardiac Ejection Fraction < 40 %
- peak VO2 < 16 ml/kg/min,
- optimal drug treatment of CHF,
- hospitalised for acute decompensation but not in intensive care
Exclusion Criteria:
- Chronic Obstructive Pulmonary Disease with FEV < 50%,
- History of stroke with walking disability, dementia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Functionnal ElectroStimulation (FES)
|
Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
|
|
Sham Comparator: SHAM
|
SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
VO2 peak
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Muscle nerve sympathetic activity (MSNA)
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
Six minutes walking test
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
DEXA
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
maximal quadriceps strengh
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
interleukin 1
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
interleukin 6
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
TNF alpha
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
CRP
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
BNP
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
score of minessota test
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
|
score of Functional independency measure
Time Frame: change between baseline and 60 days after the Functional Electromyo Stimulation
|
change between baseline and 60 days after the Functional Electromyo Stimulation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michel GALINIER, MD, PhD, University Hospital, Toulouse
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0730502
- 2008-A00330-55 (Other Identifier: Afssaps)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Noah LabsHospital Clinic of Barcelona; Maastricht University; Zuyderland Medical CentreActive, not recruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseSpain, Netherlands
-
BayerCompletedChronic Heart Failure | Chronic Heart Failure With Reduced Ejection FractionJapan
-
BayerActive, not recruitingChronic Heart Failure With Reduced Ejection Fraction | Worsening Chronic Heart FailureIndia
-
Maastricht University Medical CenterUniversity Medical Center Groningen; Maastricht UniversityWithdrawnChronic Heart Failure | Acute Decompensated Heart FailureNetherlands
-
Melana Yuzefpolskaya, MDRecruitingChronic Heart FailureUnited States
-
BayerRecruitingChronic Heart FailureSouth Korea
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
CHFDX,Inc.University of South Florida; Tampa General HospitalRecruitingDecompensated Chronic Heart FailureUnited States
-
Medical University of ViennaCompleted
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
Clinical Trials on Functionnal ElectroStimulation (FES)
-
UGECAM Rhône-AlpesHospices Civils de Lyon; University of Lyon; University of Franche-ComtéWithdrawn
-
Universitat Jaume IINCLIVA; Hospital Clínico Universitario de ValenciaCompletedHeart Failure With Normal Ejection FractionSpain
-
University Hospital, ToursINSERM UMR-1253, Tours, FranceRecruitingAutism Spectrum DisorderFrance
-
Rennes University HospitalCompletedChronic Renal Failure (CRF)France
-
Tatiane Gomes de AraujoUnknownOveractive Bladder | Parkinson DiseaseBrazil
-
TOPMEDNatural Sciences and Engineering Research Council, Canada; Kurage SAS; Clinique...Not yet recruitingStroke Sequelae | Stroke ( 3 Months After Onset)
-
University Hospital, AngersUnknownChronic Low Back PainFrance
-
Janaina Mayer de Oliveira NunesTerminatedUrinary Bladder, Overactive
-
Centre Hospitalier Universitaire de NiceCompletedFacioscapulohumeral Muscular DystrophyFrance
-
Hospital de TerrassaUnknown